Research & Development

Interdisciplinary consortium receives grant to develop next-generation cell-based cancer vaccines

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at centralized locations. Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible. In this project, dendritic cell cancer vaccines will be generated in Saint-Gobain’s VueLife® “C” Series FEP bags.

IDEAYA and GSK announce a broad partnership in Synthetic Lethality

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.  

Takeda, Neurocrine sign $2bn deal on potential therapies for psychiatric disorders

Takeda Pharmaceutical has entered into a more than $2bn worth deal with Neurocrine Biosciences to develop potential therapies for psychiatric disorders.

Cannabinoid Purification and Scale-Up on Hipersep^® Pilot

For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.

PureO₃ Dissolved Ozone Sensor

The new pureO₃ Dissolved Ozone Sensor with Intelligent Sensor Management (ISM^®) technology provides robust, reliable measurement with increased stability in pure water applications.

Autobahn Therapeutics launches with $76m Series B financing to develop next generation therapies for CNS disorders

Financing co-led by ARCH Venture Partners and Cowen Healthcare Investments

MMS to support IGY Life Sciences in advancing Covid-19 antibody candidate

IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.

AbbVie, HBM, UU, and EMC to develop Covid-19 antibody therapeutic

AbbVie has joined forces with Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) to develop a novel antibody therapeutic for the prevention and treatment of Covid-19.

Cullinan Oncology completes $98.5m Series B financing

Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio.